Literature DB >> 33680547

Red and blue light in antitumor photodynamic therapy with chlorin-based photosensitizers: a comparative animal study assisted by optical imaging modalities.

Mikhail Kirillin1, Daria Kurakina1, Aleksandr Khilov1, Anna Orlova1, Maria Shakhova1,2, Natalia Orlinskaya1,2, Ekaterina Sergeeva1.   

Abstract

The goal of this study is a comparative analysis of the efficiency of the PDT protocols for CT26 tumor model treatment in Balb/c mice employing red and blue light with both topical and intravenous administration of chlorin-based photosensitizers (PSs). The considered protocols include the doses of 250 J/cm2 delivered at 660 nm, 200 J/cm2 delivered at 405 nm, and 250 J/cm2 delivered at both wavelengths with equal energy density contribution. Dual-wavelength fluorescence imaging was employed to estimate both photobleaching efficiency, typical photobleaching rates and the procedure impact depth, while optical coherence tomography with angiography modality (OCT-A) was employed to monitor the tumor vasculature response for up to 7 days after the procedure with subsequent histology inspection. Red light or dual-wavelength PDT regimes with intravenous PS injection were demonstrated to provide the most pronounced tumor response among all the considered cases. On the contrary, blue light regimes were demonstrated to be most efficient among topical application and irradiation only regimes. Tumor size dynamics for different groups is in good agreement with the tumor response predictions based on OCT-A taken in 24h after exposure and the results of histology analysis performed in 7 days after the exposure.
© 2021 Optical Society of America under the terms of the OSA Open Access Publishing Agreement.

Entities:  

Year:  2021        PMID: 33680547      PMCID: PMC7901330          DOI: 10.1364/BOE.411518

Source DB:  PubMed          Journal:  Biomed Opt Express        ISSN: 2156-7085            Impact factor:   3.732


  3 in total

1.  Combined Fluorescence and Optoacoustic Imaging for Monitoring Treatments against CT26 Tumors with Photoactivatable Liposomes.

Authors:  Ilya Turchin; Shazia Bano; Mikhail Kirillin; Anna Orlova; Valeriya Perekatova; Vladimir Plekhanov; Ekaterina Sergeeva; Daria Kurakina; Aleksandr Khilov; Alexey Kurnikov; Pavel Subochev; Marina Shirmanova; Anastasiya Komarova; Diana Yuzhakova; Alena Gavrina; Srivalleesha Mallidi; Tayyaba Hasan
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

Review 2.  Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review.

Authors:  Lele Miao; Juan Zhang; Binjie Huang; Zhengchao Zhang; Song Wang; Futian Tang; Muzhou Teng; Yumin Li
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

Review 3.  Research Progress of Photothermal Nanomaterials in Multimodal Tumor Therapy.

Authors:  Xiaolu Shi; Ye Tian; Yang Liu; Zhengrong Xiong; Shaobo Zhai; Shunli Chu; Fengxiang Gao
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.